Loading clinical trials...

RECRUITING

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)

NCT06433752•TG Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Confirmed Multiple Sclerosis (MS) diagnosis.
•2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Exclusion Criteria

•1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
•2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
•3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

Locations (80)

TG Therapeutics Investigational Trial Site

Birmingham, Alabama, United States

TG Therapeutics Investigational Trial Site

Mobile, Alabama, United States

TG Therapeutics Investigational Trial Site

Gilbert, Arizona, United States

TG Therapeutics Investigational Trial Site

Phoenix, Arizona, United States

TG Therapeutics Investigational Trial Site

Scottsdale, Arizona, United States

TG Therapeutics Investigational Trial Site

Fresno, California, United States

TG Therapeutics Investigational Trial Site

Newport Beach, California, United States

TG Therapeutics Investigational Trial Site

Orange, California, United States

TG Therapeutics Investigational Trial Site

West Hollywood, California, United States

TG Therapeutics Investigational Trial Site

Aurora, Colorado, United States

Key Dates

Start Date

July 22, 2024

Primary Completion Date

July 1, 2027

Completion Date

July 1, 2027

Last Updated

February 27, 2026

Enrollment

500

ESTIMATED participants

Conditions

Relapsing Multiple SclerosisMultiple Sclerosis

Interventions

No Intervention

OTHER

Contacts

TG Therapeutics Clinical Support Team

CONTACT

1-877-575-8489 clinicalsupport@tgtxinc.com

Sponsors

Lead Sponsor

TG Therapeutics, Inc.

Related Studies

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions